3D Printed Drugs Market Size, Share & Growth | Forecast 2031

Report Description

The global 3D printed drugs market size was USD 307.54 Million in 2022 and is likely to reach USD 742.0 Million by 2031, expanding at a CAGR of 9.1% during 2023–2031. The market growth is attributed to the high adoption of personalized drugs.

Increasing implementation of personalized drugs is anticipated to boost the 3D printed drugs during the forecast period. 3D printing creates personalized pharmaceutical system through automated control over drug dosage and is appropriate for high and low drug concentrations. The color, shape, size, design, and taste of the drugs can be chosen by 3D printed technology. The advanced method of manufacturing has the potential to overcome many obstacles, which helps patient outcomes in solid dosage forms on the market.

Get Free Sample Report

In April 2020, FabRx Ltd., introduced the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalized medicines. The 3D printer fits with advanced in-line quality control procedures and monitors the printing process to detect faults and track the progress during manufacture.

The market report finds that the COVID-19 pandemic fueled the 3D printed drugs market. Several printers have launched by companies operating in the advanced manufacturing industry to help scale up the manufacturing of medicines and other essential products. During the pandemic, the usage of these technologies is anticipated to increase, which is likely to boost the market.

3D Printed Drugs Market Dynamics

Get Free Sample Report

Major Drivers

Increasing prevalence of chronic diseases such as Pneumonia among children and the aging population is expected to drive the 3D printed drugs market. The 3D printed medicine is easy to swallow and highly soluble which helps children and elderly people who have difficulty swallowing. The increasing number of chronic diseases in children and the geriatric population is contributing to the adoption of these drugs, which is expected to boost the market.

Existing Restraints

Lack of government regulations is expected to hamper the market. Several scams occur due to a lack of stringent regulations and result in the hacking of data stored online. This makes patients more reluctant to disclose their medical information. Moreover, mislabeling and entering wrong details on the blueprint is also a major challenge for the market. The 3D blueprint of the patient, their dosage, and medical history is required to prepare the 3D printed medicine.

Emerging Opportunities

Increasing innovative technologies for the development of 3D printed drugs, is expected to create lucrative opportunities in the market. As several companies are entering with sophisticated technologies and investing to create new drugs, which is expected to boost the market in the coming years.

• In December 2020, TRIASTEK, a global healthcare company developing medicines with pioneering 3D printing technology raised USD 15 million to accelerate the development of 3D printed drugs. TRIASTEK company uses the funds for the research and development of its 3D printed medicines along with registration applications in the US and China and the construction of large-scale production lines.

Scope of 3D Printed Drugs Market Report

The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

3D Printed Drugs Market Segment Insights

Application Segment Analysis

Based on application, the 3D printed drugs market is divided into neurology, orthopedic, dental, and others. The neurology segment is expected to expand at a significant pace during the projection period, due to the increasing prevalence of several neurological disorders such as Parkinson’s disease. The segment growth is further attributed to the increasing popularity of pharmaceutical companies, as several organizations are investing in the neurology segment thereby fueling the market.

• According to the Parkinson’s Foundation’s study in 2022, every year in the US around 90,000 individuals are diagnosed with Parkinson’s disease. This represents a vertical 50% rise from the earlier projected rate of 60,000 diagnoses every year.

The orthopedic segment is anticipated to hold a key share of the market in the coming years, as it is used to combat postoperative infections. Orthopedic procedures are complex and difficult. New approaches are needed to overcome many known issues and improve patient outcomes. Furthermore, high rates of complications, especially infections, often result in prolonged patient suffering and functional impairment, which is expected to boost the segment.

Get Free Sample Report

Technology Segment Analysis

On the basis of technology, the global market is segregated into fused deposition modeling, inkjet printing, zip dose technology, and others. The inkjet printing segment is projected to register a considerable CAGR during the forecast period, due to the technological advancements that make it easier to use. Inkjet printing includes spraying numerous combinations of active pharmaceutical ingredients and excipients through a nozzle to deposit 3D structures in solid dosage forms. It makes 3D drugs at a consistent rate and offers technical advantages compared to other processes. The segment growth is further attributed to the increasing epilepsy rates, technical breakthroughs in 3D printing technology, and rising awareness of inkjet printing technology in market players.

The fused deposition modeling (FDM) segment is anticipated to account for a major market share in the coming years, as it is used for production applications, fabrication, and mechanical system modeling. FDM printers are appropriate with a variety of thermoplastic polymers such as ABS and PLA and polycarbonates such as PS, PET, PVA, nylon, ASA, and even complex filaments that are based on wood, metal, stone, and others. These composites often offer stimulating mechanical properties such as conductive, biocompatible, or heat resistant.

Get Free Sample Report

Dosage Form Segment Analysis

In terms of dosage form, the 3D printed drugs market is segmented into capsules, tablets, nanoparticles, and others. The tablets segment is expected to register a robust growth rate during the forecast period, as 3D printed drugs are available in the form of tablets. The tablet size, form, shape, and rate of delivery of a wide range of drugs are easily adjustable. Printing tablets are coated with a more absorbent surface, which helps them to dissolve faster and without additional liquid intake than with conventional tablet presses. It is also equipped with more active ingredients.

Product Type Segment Analysis

Based on product type, the global market is bifurcated into spritam drug and others. The spritam drug segment is anticipated to expand at the fastest growth rate during the projection period, as it is an adjunctive therapy in the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures in people with epilepsy. Spritam uses the Zip Dose technology platform, which creates an absorbent formulation through 3D printing, allowing the formulation to quickly bust with a single sip of liquid. Spritam is the first 3D (three-dimensional) printed drug product that was approved by the Food and Drug Administration in 2015.

End-user Segment Analysis

On the basis of end-user, the 3D printed drugs market is divided into hospitals, clinics, research institutes, and others. The hospitals segment is expected to register a considerable CAGR during the forecast period, owing to the widespread use of prescription pills to treat a variety of diseases. The segment growth is further attributed to the increasing demand for pharmaceuticals and the use of cost-effective bio-drugs. In hospitals, these printers are installed to enable on-demand manufacturing of medicines, especially those with poor stability or those that need to be stored in cold chains. Additionally, it save waste, expenses, and environmental stress to a great extent. These factors are expected to raise the adoption of 3D-printed medicines in hospitals and clinics.

• In February 2020, Aprecia Pharmaceuticals, LLC., partnered with Purdue University’s College to launch a comprehensive collaboration on future 3DP Pharmaceuticals equipment and medications. Aprecia’s mission is to enlarge and increase its 3DP technology platform through global partnerships that offer pharmaceutical solutions to fulfill patient needs.

Regional Analysis

In terms of region, the global 3D printed drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the increasing incidence of chronic disease and rising investments in research & development activities. The regional market growth is further attributed to the presence of excellent domestic healthcare infrastructure and the high use of technological developments.

• According to the American Hospital Association, around 133 million Americans suffer from chronic diseases such as arthritis, hypertension, and heart disease. Approximately 15 million higher than just a decade ago and this number is estimated to reach around 170 million by 2030.

The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, owing to the increasing technological developments and usage of 3D printed drug methodologies in China and Japan. Increasing development of healthcare infrastructures, clinical development frameworks, and research & development activities in emerging countries such as India and Australia are expected to boost the 3D printed drugs market in the region.

Get Free Sample Report